Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biol...

Full description

Bibliographic Details
Main Authors: Antonio Vitale, Laura Obici, Marco Cattalini, Giuseppe Lopalco, Giampaolo Merlini, Nicola Ricco, Alessandra Soriano, Francesco La Torre, Elena Verrecchia, Antonella Insalaco, Lorenzo Dagna, Masen Abdel Jaber, Davide Montin, Giacomo Emmi, Luisa Ciarcia, Sara Barneschi, Paola Parronchi, Piero Ruscitti, Maria Cristina Maggio, Ombretta Viapiana, Jurgen Sota, Carla Gaggiano, Roberto Giacomelli, Ludovico Luca Sicignano, Raffaele Manna, Alessandra Renieri, Caterina Lo Rizzo, Bruno Frediani, Donato Rigante, Luca Cantarini
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Medicine
Subjects:
tumor necrosis factor receptor-associated periodic syndrome
biologic therapy
personalized medicine
interleukin-1 inhibitors
tumor necrosis factor inhibitors
tocilizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.668173/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.668173/full

Similar Items